Source / information
Published by:
Source:
Healio interview
Disclosure:
Healio is media partner for Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases. Handelsman is the Medical Director and Principal Investigator of the Metabolic Institute of America and the Chair of the Task Force.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.
Back to Healio
A group of leading experts in cardiology, endocrinology and nephrology will meet for a workshop to discuss best practices in the management of diabetes in cardiorenal metabolic diseases with the aim of producing a new consensus statement.
The two-day workshop Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases was designed to develop an interdisciplinary consensus on disease management at the interface of cardiology, endocrinology and nephrology. The workshop is only available by invitation to experts and supporters who have the opportunity to contribute to Q&A sessions and participate in an open townhall discussion. The task force will operate in a think tank, the Diabetes Cardiorenal & Metabolism Institute, or DCMi, which is also affiliated with the Metabolic Endocrine Education Foundation, a 501c3 charity.
Source: Adobe Stock
The event will take place in person and virtually Friday and Saturday at the Grand Hyatt DFW in Dallas.
Yehuda Handelsman
“What is happening this weekend is an educational activity where we are looking at what parameters should be covered for a possible clinical practice recommendation,” member of the editorial board of Endocrine Today Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, medical director and chief investigator for the Metabolic Institute of America in Tarzana, Calif., and chair of the task force, said Healio. “The specialties are now converging. For example, a drug such as the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) is a drug for endocrinologists, cardiologists and nephrologists. How should it be used? How do you reconcile the different needs? All of these large outcome studies for these drugs that bring these specialists together has created a lot of confusion about what to do and how best to do it. “
Contemporary CV outcome studies transcend the traditional medical field and span the various disciplines of the cardiorenal metabolic space, Handelsman said in an interview. Not a single medical society is able to develop diverse and comprehensive guidelines, he said.
The goal of the initiative is to “fill the void” and develop consensus across multiple specialties, with clinical recommendations aimed at specialists and primary care physicians, with an emphasis on non-experts, to make the recommendations clinical and easy to implement. The recommendations are published in a peer-reviewed journal and are available free of charge to educational institutions, Handelsman said.
The Task Force Working Group members, all volunteers, are well-known experts in the field of diabetes and cardiovascular disease, including past presidents and senior executives of major corporations such as the American Diabetes Association, the American Heart Association, and the American Association of Clinical Endocrinology, the Heart Failure Society Failure of America, American College of Cardiology, Kidney Disease Improving Global Outcomes, and others.
The agenda includes 20 thematic areas that span the three subject areas, including lifestyle, education, lipids, technology, tests to assess comorbidities, high blood pressure, hyperglycemia and hypoglycemia, anticoagulation and inflammation, and contemporary prevention of diseases such as non-alcoholic fatty liver disease, atherosclerotic CVD, HF and chronic kidney disease.
“For the cardiologist, the endocrinologist, the nephrologist, it is important that we all communicate – what is important when treating such a patient?” Said Handelsmann. “You can’t focus on a condition, a disease. You have to see the whole patient. “
Further information on the workshop meeting or the DCMi can be found at www.DCRMI.com.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.
Back to Healio
